C-YGSXMagnitude Biosciences
C. elegans, whole-organism HTS, automated imaging
research tools
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YGSX
C-YGSXC-YGSXC. elegans, whole-organism HTS, automated imaging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In the visible text of the 2022-01-24 Wayback snapshot, Magnitude Biosciences does not display an explicit beliefs or mission paragraph. The page does state, through its navigation and service framing, that the company is focused on using C. elegans and related technology to support research and commercial work in ageing, the microbiome, neurodegeneration, toxicity, and transgenics for biotech, pharma, health/manufacturing, and academia.
SourceMagnitude Biosciences presents the view that ageing can be meaningfully tested and potentially slowed by compounds or other interventions, and that these effects can be measured quickly and reliably through C. elegans healthspan assays. Its homepage emphasizes precise protocols, automation, movement monitoring, reproducibility, and cost-effective large-scale testing as the basis for generating useful ageing research data.
SourceMagnitude Biosciences presents the view that improving healthspan is an important goal and that C. elegans is an effective model for answering research questions in ageing, neurodegeneration, microbiome, and toxicity. The company states that worms are large enough for relevance and reproducibility yet small enough for cost and time efficiency, and that non-invasive measurement of movement, mobility, speed, and behaviour can provide meaningful readouts on health and ageing.
SourceMagnitude Biosciences states that C. elegans is a practical and relevant model organism for biomedical research because it is large enough to be relevant to human disease, small enough to improve cost and time efficiency, and useful for de-risking the transition from cell-based studies to mouse models. The company also presents its automated imaging, multiple functional endpoints, fast data analysis, and customised gene-edited disease models as enabling faster compound testing and high-quality research services.
Source